5. Conclusions
COLD SYMPTOMS, COMMON COLD
In conclusion, we performed in vitro experiments and an RCT to evaluate whether LG2055 suppresses common cold symptoms by activating pDCs in healthy adults. Our results showed that LG2055 activated pDCs in vitro, and that a daily intake of LG2055 decreased the cumulative days of common cold symptoms in healthy adults. Furthermore, the expression of CD86 and HLA-DR in the LG2055 group was higher than that in the placebo group among the participants with a low secretory rate of salivary sIgA. These results suggest that LG2055 intake suppresses the subjective symptoms of the common cold by activating pDCs and improving the host’s immune system in healthy adults, especially in immune-weakened adults.